No black box warning on record for Aspirin And Extended-Release Dipyridamole

As of the latest FDA labeling reviewed, Aspirin And Extended-Release Dipyridamole (ASPIRIN AND EXTENDED-RELEASE DIPYRIDAMOLE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Aspirin And Extended-Release Dipyridamole medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Aspirin and extended-release dipyridamole capsules increases the risk of bleeding ( 5.1 ) Avoid use in patients with severe hepatic or renal insufficiency ( 5.2 , 5.3 ) Interrupt aspirin and extended-release dipyridamole capsules 48 hours before using intravenous dipyridamole or other adenosinergic agents for stress testing ( 5.6 , 7.1 ) 5.1 Risk of Bleeding Aspirin and

No black box warning on record for Aspirin And Extended-Release Dipyridamole

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Aspirin and extended-release dipyridamole capsules increases the risk of bleeding ( 5.1 ) Avoid use in patients with severe hepatic or renal insufficiency ( 5.2 , 5.3 ) Interrupt aspirin and extended-release dipyridamole capsules 48 hours before using intravenous dipyridamole or other adenosinergic agents for stress testing ( 5.6 , 7.1 ) 5.1 Risk of Bleeding Aspirin and

Aspirin And Extended-Release Dipyridamole Black Box Warning

No black box warning on record for Aspirin And Extended-Release Dipyridamole

Other warnings & precautions

Aspirin And Extended-Release Dipyridamole Black Box Warning

No black box warning on record for Aspirin And Extended-Release Dipyridamole

Other warnings & precautions